NV-BITSENSING
12.1.2021 13:02:35 CET | Business Wire | Press release
bitsensing , a South Korean radar technology startup, introduces the new mini Healthcare Radar, mini-H , the smallest high-resolution 60GHz IoT Radar sensor in the lineup. The innovation behind the mini-H demonstrates the company’s industry leading expertise in designing and building cutting edge radar technology that can transform healthcare, automotive, mobility, smart home, security, and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210112005325/en/
Dr. Jae-Eun Lee, CEO of bitsensing, a seasoned engineer in radar technology and formerly a part of the automotive world at Mando Corp., knows what it takes to create a safe and conveniently connected world. “Revolutionary technologies such as mini-H are propelling what is possible in all facets of our daily lives,” says Lee. “We at bitsensing are committed to integrating these groundbreaking radar technologies to help build smart lives and smart cities which ultimately elevates the quality of life for all.”
The advanced mini-H sensor attaches to the wall and can detect, in real-time, presence, movement, breathing or lack thereof, and falls by measuring breathing patterns and pulsating vessels without the use of intrusive cameras or wearables.
Specifically designed for a more intelligent and safer monitoring system for telehealth, mini-H can be used in dark or wet places and works regardless of clothes or blankets. The Bluetooth and WiFi communication module allows for a seamless transfer of data from the radar to dashboards or the app for easy tracking. This fully wireless product makes it quick and easy to implement software advancements, ensuring the product is always up to date. The sleek, compact aesthetic of the product also allows for an easy integration while the plug and play style provides instant monitoring of activities with the option to adjust settings for optimal personalization.
As a leading radar solution company, bitsensing offers complete end to end services, creating customizable radars like the mini-H that exceed industry standards in convenience and security. The nimble structure of bitsensing allows the team to deliver powerful products quickly while working directly with end customers across a large range of industries to ensure satisfaction and broaden their horizons of what is possible in a smart life.
CES attendees can visit bitsensing’s virtual booth to learn more about the mini-H from January 11-14, 2021. To view the mini-H informational product video, please visit here . If you are interested in learning more about our radar solution offerings, please visit www.bitsensing.com .
mini-H Product Specifications
Specs subject to change without notice. All functionality, features, specifications and other product information provided in this document including, but not limited to, the benefits, design, pricing, components, performance, availability, and capabilities of the product are subject to change without notice.
General Spec |
|
Centered Frequency |
61 GHz |
Bandwidth |
3.75 GHz |
Communication Interface |
WiFi or Bluetooth, RS485 |
Coverage Spec |
|
Detection Range |
0.2m ~ 2.5m |
Field of View |
±60° (Azimuth), ±60° (Elevation) |
Feature |
Moving, Falling, Presence, Apnea |
Vital Sign |
Respiration* |
Resolution |
0.04m |
Electrical Spec |
|
Operating Voltage |
7V ~ 14V |
Current Consumption |
Max 3W |
Mechanical Spec |
|
Dimensions |
50 x 50 x 15 mm |
Weight |
100g** |
Connector |
Open terminal Cable |
Environment Spec |
|
Operating Temperature |
-20 ~ +85 °C |
* The data driven by respiration detection may be limited and is designed to be used for apnea detection |
** The weight is without cable |
About bitsensing
bitsensing is an imaging radar technology company committed to building safer smart cities and elevating connected living by designing cutting-edge sensor fusions and AI solutions bringing an unprecedented level of intelligence to smart living. Founded in 2018 by seasoned automotive experts, bitsensing is one of the only startups delivering optimal technologies that meet and exceed the high level of safety and convenience that the industry demands. bitsensing is transforming possibilities to bring democratization of smart life in healthcare, automotive, mobility, smart home, security, and beyond.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005325/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom